Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Frozen FluMist · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | FluMist |
| 2 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| Frozen FluMist® | BIOLOGICAL | Monovalent vaccine is supplied in intranasal sprayers containing 0.5 mL. |
| Placebo | OTHER | - |
Inclusion Criteria: * Male or female, 18 to 49 years of age (not yet reached their 50th birthday) at the time of study vaccination * Healthy by medical history and health assessment * Sexually active females, unless surgically sterile or at least 1 year post-menopausal, must have used an effective ...
Frozen FluMist is an investigational monoclonal antibody developed by AstraZeneca PLC. It has been studied in a Phase 2 clinical trial in healthy adult volunteers. The specific medical conditions it is intended to treat have not been disclosed. It is not yet approved for any use.
Frozen FluMist is being developed by AstraZeneca PLC, which trades on the Nasdaq under the ticker symbol AZN. AstraZeneca is the sponsor of the clinical program for this monoclonal antibody candidate.
Frozen FluMist is in Phase 2 clinical development. One Phase 2 trial has been completed, and no active trials are currently listed. The drug remains investigational and has not been approved by the FDA or any other regulatory agency.
Frozen FluMist has been evaluated in one completed Phase 2 trial, NCT00480155, titled A Study to Evaluate the Safety of a Monovalent Vaccine in Healthy Adults. The trial enrolled 300 healthy adult volunteers in the United States and was randomized, double-blind, and placebo-controlled.
Yes, Frozen FluMist and Frozen FluMist® refer to the same investigational monoclonal antibody developed by AstraZeneca PLC. The registered trademark symbol is simply a notation of the brand name and does not indicate a different product or formulation.